These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 19637820)

  • 21. Predictive value of early 18F-fluoro-deoxyglucose positron emission tomography in chemosensitive relapsed lymphoma.
    Schot B; van Imhoff G; Pruim J; Sluiter W; Vaalburg W; Vellenga E
    Br J Haematol; 2003 Oct; 123(2):282-7. PubMed ID: 14531910
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome.
    Haioun C; Itti E; Rahmouni A; Brice P; Rain JD; Belhadj K; Gaulard P; Garderet L; Lepage E; Reyes F; Meignan M
    Blood; 2005 Aug; 106(4):1376-81. PubMed ID: 15860666
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Early therapy monitoring with FDG-PET in aggressive non-Hodgkin's lymphoma and Hodgkin's lymphoma.
    Torizuka T; Nakamura F; Kanno T; Futatsubashi M; Yoshikawa E; Okada H; Kobayashi M; Ouchi Y
    Eur J Nucl Med Mol Imaging; 2004 Jan; 31(1):22-8. PubMed ID: 14574514
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Single-agent MOR208 salvage and maintenance therapy in a patient with refractory/relapsing diffuse large B-cell lymphoma: a case report.
    Jurczak W; Bryk AH; Mensah P; Gałązka K; Trofimiuk-Müldner M; Wyrobek Ł; Sawiec A; Skotnicki AB
    J Med Case Rep; 2016 May; 10(1):123. PubMed ID: 27178351
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunochemotherapy in indolent non-Hodgkin's lymphoma.
    Czuczman MS
    Semin Oncol; 2002 Apr; 29(2 Suppl 6):11-7. PubMed ID: 12040529
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rituximab combined with CHOP for successful treatment of aggressive recurrent, pediatric B-cell large cell non-Hodgkin's lymphoma.
    Jetsrisuparb A; Wiangnon S; Komvilaisak P; Kularbkaew C; Yutanawiboonchai W; Mairieng E
    J Pediatr Hematol Oncol; 2005 Apr; 27(4):223-6. PubMed ID: 15838396
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interim FDG-PET improves treatment failure prediction in primary central nervous system lymphoma: An LOC network prospective multicentric study.
    Rozenblum L; Houillier C; Baptiste A; Soussain C; Edeline V; Naggara P; Soret M; Causse-Lemercier V; Willems L; Choquet S; Ursu R; Galanaud D; Belin L; Hoang-Xuan K; Kas A
    Neuro Oncol; 2024 Jul; 26(7):1292-1301. PubMed ID: 38366824
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Computed tomography and 18F-FDG positron emission tomography for therapy control of Hodgkin's and non-Hodgkin's lymphoma patients: when do we really need FDG-PET?
    Reinhardt MJ; Herkel C; Altehoefer C; Finke J; Moser E
    Ann Oncol; 2005 Sep; 16(9):1524-9. PubMed ID: 15946979
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 18FDG positron emission tomography versus 67Ga scintigraphy as prognostic test during chemotherapy for non-Hodgkin's lymphoma.
    Zijlstra JM; Hoekstra OS; Raijmakers PG; Comans EF; van der Hoeven JJ; Teule GJ; Jonkhoff AR; v Tinteren H; Lammertsma AA; Huijgens PC
    Br J Haematol; 2003 Nov; 123(3):454-62. PubMed ID: 14617005
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combination of rituximab, cyclophosphamide, and vincristine induces complete hematologic remission of splenic marginal zone lymphoma.
    Arcaini L; Orlandi E; Scotti M; Brusamolino E; Passamonti F; Burcheri S; Colombo N; Vanelli L; Sbalzarini G; Lazzarino M
    Clin Lymphoma; 2004 Mar; 4(4):250-2. PubMed ID: 15072617
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Usefulness of [18F]FDG-PET kinetic analysis in non-enhancing primary central nervous system lymphoma: case report.
    Kawai N; Kawanishi M; Tamiya T; Nagao S
    Ann Nucl Med; 2005 Jul; 19(5):415-9. PubMed ID: 16164200
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immune evasion via PD-1/PD-L1 on NK cells and monocyte/macrophages is more prominent in Hodgkin lymphoma than DLBCL.
    Vari F; Arpon D; Keane C; Hertzberg MS; Talaulikar D; Jain S; Cui Q; Han E; Tobin J; Bird R; Cross D; Hernandez A; Gould C; Birch S; Gandhi MK
    Blood; 2018 Apr; 131(16):1809-1819. PubMed ID: 29449276
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rituximab-CHOP or 2-weekly CHOP + G-CSF in aggressive lymphoma of the elderly?
    Bernardi D; Giacalone A; Spina M; Tirelli U
    Ann Oncol; 2004 Aug; 15(8):1298. PubMed ID: 15277275
    [No Abstract]   [Full Text] [Related]  

  • 34. Fluorine-18-fluorodeoxyglucose positron emission tomography in response assessment before high-dose chemotherapy for lymphoma: a systematic review and meta-analysis.
    Terasawa T; Dahabreh IJ; Nihashi T
    Oncologist; 2010; 15(7):750-9. PubMed ID: 20587551
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 18F-fluoro-deoxy-glucose positron emission tomography (18F-FDG-PET) for assessment of enteropathy-type T cell lymphoma.
    Hoffmann M; Vogelsang H; Kletter K; Zettinig G; Chott A; Raderer M
    Gut; 2003 Mar; 52(3):347-51. PubMed ID: 12584214
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Alternated versus syncopated CHOP-PVB: two studies for the treatment of non-Hodgkin's lymphoma by the Southwest Oncology Group.
    Dabich L; Dahlberg S; Hartsock RJ; LoBuglio AF; Liepman MK; Grozea PN; Eyre HJ; Weick JK; Bonnet JD; Coltman CA
    Cancer Invest; 1991; 9(6):613-20. PubMed ID: 1721000
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rituximab-CHOP or two-weekly CHOP + G-CSF in aggressive lymphoma of the elderly?
    Todeschini G; Gelio S; Tecchio C
    Ann Oncol; 2004 Mar; 15(3):538-9. PubMed ID: 14998863
    [No Abstract]   [Full Text] [Related]  

  • 38. Successful treatment of gastrointestinal follicular lymphoma with rituxan and combination chemotherapy.
    Al-Salman J; Salib H; Boonswang P
    Med Oncol; 2001; 18(4):277-83. PubMed ID: 11918454
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Improved complete remission rates and survival for patients with large cell lymphoma treated with chemoimmunotherapy. A Southwest Oncology Group Study.
    Jones SE; Grozea PN; Metz EN; Haut A; Stephens RL; Morrison FS; Talley R; Butler JJ; Byrne GE; Hartsock R; Dixon D; Salmon SE
    Cancer; 1983 Mar; 51(6):1083-90. PubMed ID: 6185212
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A case of nodular sclerosis Hodgkin's lymphoma repeatedly relapsing in the context of composite plasma cell-hyaline vascular Castleman's disease: successful response to rituximab and radiotherapy.
    Falchi L; Capello D; Palumbo B; Rauco A; Emili R; Cianciulli M; Pace R; Capparella V; Liberati F; Liberati AM
    Eur J Haematol; 2007 Nov; 79(5):455-61. PubMed ID: 17908180
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.